Skip to main content

Published locations for Psoriasis: Brodalumab maintains efficacy through 144 weeks

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Psoriasis: Brodalumab maintains efficacy through 144 weeks

User login

  • Reset your password
  • /content/psoriasis-brodalumab-maintains-efficacy-through-144-weeks
  • /edermatologynews/article/88845/psoriatic-arthritis/psoriasis-brodalumab-maintains-efficacy-through
  • /rheumatologynews/article/88845/psoriatic-arthritis/psoriasis-brodalumab-maintains-efficacy-through
  • /rheumatology/article/88845/psoriatic-arthritis/psoriasis-brodalumab-maintains-efficacy-through-144
  • /dermatology/article/88845/psoriatic-arthritis/psoriasis-brodalumab-maintains-efficacy-through-144
  • /dermatology/psoriasiscollection/article/88845/psoriatic-arthritis/psoriasis-brodalumab-maintains
  • /psoriatic-arthritis-icymi/article/88845/psoriatic-arthritis/psoriasis-brodalumab-maintains-efficacy